The ARTISTRY-1 trial is a randomized, open-label, phase 3 clinical trial that investigated switching to a single-tablet regimen of bictegravir–lenacapavir in adult HIV-1 patients who were already virologically suppressed but were taking complex antiretroviral regimens.[3] This single-tablet regimen has demonstrated non-inferior efficacy compared to complex regimens.[1] Efficacy was in maintaining viral suppression in patients.[1][3] The safety profile was similar to the original comprehensive regimens.[1] Patients reported increased treatment satisfaction after switching to a single-tablet regimen.[1] Bictegravir-lenacapavir thus offers new options for optimizing HIV-1 treatment in people with complex regimens.[1]